NCT02973789 2026-03-18
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Phase 3 Completed
Clinical Trials
42 trialsNCT05941741 2026-03-18
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Sun Yat-sen University
Phase 3 Recruiting
NCT07359040 2026-03-12
Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Peking University People's Hospital
Active not recruiting
NCT07466225 2026-03-12
HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion
Peking University
Not yet recruiting
NCT07466238 2026-03-12
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Not yet recruiting
NCT07468630 2026-03-12
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2 Recruiting
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT07457099 2026-03-09
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Zhujiang Hospital
Not yet recruiting
NCT06647680 2026-03-06
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）
The Affiliated Hospital of Qingdao University
Phase 2 Recruiting
NCT07453342 2026-03-06
Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
Peking Union Medical College Hospital
Recruiting
NCT06502691 2026-03-02
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
University of Washington
Phase 1/2 Recruiting
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07110103 2026-02-27
JACKPOT38
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT06802757 2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07427186 2026-02-25
MINER2
Institut Claudius Regaud
Phase NA Not yet recruiting
NCT07428252 2026-02-25
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07434518 2026-02-25
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting
NCT03514368 2026-02-19
MINER
Institut Claudius Regaud
Phase NA Recruiting
NCT04913311 2026-02-19
Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Recruiting
NCT06524570 2026-02-18
iFOCUS
UMC Utrecht
Phase 1 Recruiting
NCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT06964568 2026-02-10
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University
Phase 3 Recruiting
NCT06610734 2026-02-09
SKY
Sichuan University
Phase 2 Recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT07389876 2026-02-05
G/GEJ
Fudan University
Recruiting
NCT07385989 2026-02-04
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06627712 2026-01-30
SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC
West China Hospital
Phase 3 Recruiting
NCT06283238 2026-01-29
Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)
Duke University
Withdrawn
NCT05166239 2026-01-23
HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT
Peking University
Phase 2 Completed
NCT07363369 2026-01-23
Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
West China Hospital
Phase 1 Not yet recruiting
NCT07364305 2026-01-23
Lalo
Eastern Hepatobiliary Surgery Hospital
Phase 2 Recruiting
NCT04995003 2026-01-22
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
Phase 1 Recruiting
NCT06190275 2026-01-21
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
Grit Biotechnology
Phase NA Recruiting
NCT07339488 2026-01-14
ILDR-03
Shantou University Medical College
Phase 2 Active not recruiting
NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07317778 2026-01-05
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07230639 2025-12-26
MODIFI-CC
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT07279077 2025-12-26
MODIFI-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting